ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀå : °Ë»ç À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Frasier Syndrome Market, By Test Type (Genetic Testing, Ultrasound Testing, Others), By End User (Hospitals, Diagnostic Centers, Research Institutes, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
»óǰÄÚµå
:
1741463
¸®¼Ä¡»ç
:
Coherent Market Insights
¹ßÇàÀÏ
:
2025³â 03¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀåÀº 2025³â 1¾ï 5,580¸¸ ´Þ·¯, 2032³â¿¡´Â 2¾ï 2,070¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)Àº 5.1%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.
º¸°í¼ ¹üÀ§ |
º¸°í¼ »ó¼¼ |
±âÁØ ¿¬µµ |
2024 |
2025³â ½ÃÀå ±Ô¸ð |
1¾ï 5,580¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ |
2020-2024³â |
¿¹Ãø ±â°£ |
2025-2032³â |
¿¹Ãø ±â°£(2025-2032³â) CAGR |
5.10% |
2032³â °¡Ä¡ ¿¹Ãø |
2¾ï 2,070¸¸ ´Þ·¯ |
ÇÁ·¹ÀÌÀú ÁõÈıº(FS)Àº ½ÅÀå°ú ¼º ¹ß´Þ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Èñ±ÍÇÑ À¯Àü ÁúȯÀÔ´Ï´Ù. ÇÁ·¹ÀÌÀú ÁõÈıºÀº ¸»±â ½ÅºÎÀüÀ¸·Î ÁøÇàµÉ ¼ö ÀÖ´Â ½ÅÀå Áúȯ°ú ¿©¼ºÀÇ ¿ù°æ Áֱ⠺ÎÁ·À¸·Î À̾îÁö´Â ¼º¼± Çü¼º ÀÌ»óÀÌ Æ¯Â¡ÀÔ´Ï´Ù.
1964³â ÇÁ¶ó´õ ¹Ú»ç´Â ÇÁ·¹ÀÌÀú ÁõÈıºÀ̶ó´Â ¿ë¾î¸¦ ¸¸µé¾î³Â½À´Ï´Ù. ÇÁ·¹ÀÌÀú ÁõÈıºÀº 11¹ø ¿°»öü ´Ü¿Ï¿¡ ÀÖ´Â WT1 À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ÀÌ À¯ÀüÀÚ´Â ¹è¾Æ ¹ß»ý±âÀÇ ½ÅÀå°ú »ý½Ä¼±ÀÇ ¹ß´Þ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, WT1 À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ´Â Á¤»óÀûÀÎ ¼¼Æ÷ °úÁ¤À» ÆÄ±«ÇÏ¿© ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ Æ¯Â¡ÀûÀΠƯ¡À» °¡Á®¿É´Ï´Ù.
ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ ¹ßº´·üÀº Ãâ»ý¾Æ 10¸¸ ¸í´ç 1¸íÀ¸·Î ÃßÁ¤µË´Ï´Ù. ÁÖ·Î ¿©¼º¿¡°Ô ¹ßº´ÇÏÁö¸¸ µå¹°°Ô ³²¼º¿¡°Ôµµ ¹ßº´ÇÑ »ç·Ê°¡ º¸°íµÇ°í ÀÖ½À´Ï´Ù. ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ Áø´ÜÀº ÀÓ»óÀû Ư¡, À¯ÀüÀÚ °Ë»ç, ½ÅÀå Á¶Á÷ÀÇ º´¸®Á¶Á÷ÇÐÀû °Ë»ç¿¡ ±Ù°ÅÇÏ¿© ÀÌ·ç¾îÁý´Ï´Ù.
½ÃÀå ¿ªÇÐ:
ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ù°, À¯Àü¼º Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÷´Ü Áø´Ü ±â¼úÀÇ ¹ß´Þ·Î ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ Áø´ÜÀ²ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú, À¯ÀüÀÚ °Ë»ç ¹× ½ºÅ©¸®´×¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
µÑ°, ÇÁ·¹ÀÌÀú ÁõÈıºÀÇ À¯º´·ü Áõ°¡µµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. È¿°úÀûÀÎ ½ÅÀå ´ëü ¿ä¹ý°ú Àå±âÀûÀÎ °ü¸® Àü·«ÀÇ Çʿ伺Àº Çõ½ÅÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù.
±×·¯³ª ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀåµµ ÀÏÁ¤ÇÑ ¾ïÁ¦¿äÀο¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÌ Èñ±ÍÁúȯ¿¡ ´ëÇÑ ÀÇ·á Àü¹®°¡¿Í ÀϹÝÀÎÀÇ ÀνÄÀÌ Á¦ÇÑÀûÀ̱⠶§¹®¿¡ Áø´ÜÀÌ ´Ê¾îÁö°Å³ª Ä¡·á°¡ Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯ÀüÀÚ °Ë»ç ¹× Àü¹® Ä¡·á¿¡ ¼Ò¿äµÇ´Â °í°¡ÀÇ ºñ¿ëÀº ȯÀÚ¿Í ±× °¡Á·¿¡°Ô Å« ºÎ´ãÀ¸·Î ÀÛ¿ëÇÕ´Ï´Ù.
ÀÌ·¯ÇÑ ¾î·Á¿ò¿¡µµ ºÒ±¸Çϰí ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀå¿¡´Â ¸î °¡Áö ±âȸ°¡ ÀÖ½À´Ï´Ù. Ç¥Àû Ä¡·á¿Í ¸ÂÃã ÀÇ·áÀÇ °³¹ß·Î ÇÁ·¹ÀÌÀú ÁõÈıº ȯÀÚÀÇ ¿¹Èİ¡ °³¼±µÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ¶ÇÇÑ, ¿¬±¸±â°ü, Á¦¾àȸ»ç, Áö¿ø´ÜüÀÇ Çù·ÂÀ¸·Î ´õ ³ªÀº Áø´Ü µµ±¸¿Í Ä¡·á¹ý ¿¬±¸¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
- ¼¼°èÀÇ ÇÁ·¹ÀÌÀú ÁõÈıº(Frazier Syndrome) ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© 2025-2032³â°£ ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR) µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
- ÀÌ º¸°í¼´Â ´Ù¾çÇÑ ºÎ¹®ÀÇ ÀáÀçÀû ¼öÀÍ Ã¢Ãâ ±âȸ¸¦ ÆÄ¾ÇÇϰí, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
- ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ ÁÖ¿ä °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
- ÀÌ º¸°í¼´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.
- ÀÌ º¸°í¼ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
- ÀÌ º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
- ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
- º¸°í¼ ¼³¸í
- ÁÖ¿ä ¿ä¾à
- Coherent Opportunity Map(COM)
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
- ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀÎ
- ¼ºÀå ¾ïÁ¦¿äÀÎ
- ±âȸ
- ¿µÇ⠺м®
- ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
- ±ÔÁ¦ ½Ã³ª¸®¿À
- Á¦Ç° ¹ß¸Å ¹× ½ÂÀÎ
- PEST ºÐ¼®
- PORTER ºÐ¼®
- ÀμöÇÕº´(M&A) ½Ã³ª¸®¿À
Á¦4Àå ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ
- COVID-19 ¿ªÇÐ
- °ø±ÞÃø°ú ¼ö¿äÃø ºÐ¼®
- °æÁ¦¿¡ ´ëÇÑ ¿µÇâ
Á¦5Àå ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀå, °Ë»ç À¯Çüº°, 2020³â-2032³â
- À¯ÀüÀÚ °Ë»ç
- ÃÊÀ½ÆÄ °Ë»ç
- ±âŸ
Á¦6Àå ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020³â-2032³â
- º´¿ø
- Áø´Ü¼¾ÅÍ
- ¿¬±¸±â°ü
- ±âŸ
Á¦7Àå ÇÁ·¹ÀÌÀú ÁõÈıº ½ÃÀå, Áö¿ªº°, 2020³â-2032³â
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÀÌÅ»¸®¾Æ
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ·¯½Ã¾Æ
- ±âŸ À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- ASEAN
- È£ÁÖ
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ¸ß½ÃÄÚ
- ¾Æ¸£ÇîÆ¼³ª
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
- 秵- ¾ÆÇÁ¸®Ä«
- ºÏ¾ÆÇÁ¸®Ä«
- Áß¾Ó¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«
Á¦8Àå °æÀï ±¸µµ
- Thermo Fisher Scientific
- Invitae Corporation
- GE Healthcare
- Koninklijke Philips N.V.
- Mindray Medical
- Siemens
- Invitae Corporation
- Canon Medical Systems Corporation
- FUJIFILM Sonosite Inc.
- ESAOTE SPA
- SAMSUNGHEALTHCARE
- Empire Genomics Inc.
- BPL Medical Technologies
- Trivitron Healthcare
- Hitachi Healthcare
Á¦9Àå ¼½¼Ç
LSH
¿µ¹® ¸ñÂ÷
Frasier Syndrome Market is estimated to be valued at USD 155.8 Mn in 2025 and is expected to reach USD 220.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.
Report Coverage |
Report Details |
Base Year: |
2024 |
Market Size in 2025: |
USD 155.8 Mn |
Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: |
5.10% |
2032 Value Projection: |
USD 220.7 Mn |
Frasier syndrome (FS) is a rare genetic disorder that affects the kidneys and sexual development. It is characterized by the presence of kidney disease, which can progress to end-stage renal disease, and the development of gonadal dysgenesis, leading to the absence of menstrual cycles in females.
Dr. Prader in 1964 coined the term Frasier syndrome. It is caused by mutations in the WT1 gene located on the short arm of chromosome 11. This gene plays a crucial role in the development of the kidneys and gonads during embryogenesis. Mutations in the WT1 gene disrupt normal cellular processes, leading to the characteristic features of Frasier syndrome.
The incidence of Frasier syndrome is estimated to be around 1 in 100,000 live births. It predominantly affects females, although rare cases have been reported in males as well. The diagnosis of Frasier syndrome is based on clinical features, genetic testing, and histopathological examination of kidney tissue.
Market Dynamics:
The market for Frasier syndrome is driven by several factors. Firstly, rising awareness about genetic disorders and the availability of advanced diagnostic techniques have led to an increased diagnosis rate of Frasier syndrome. This has resulted in a growing demand for genetic tests and screenings, driving market growth.
Secondly, the increasing prevalence of Frasier syndrome has also contributed to market expansion. The need for effective renal replacement therapies and long-term management strategies has created a demand for innovative treatment options.
However, the market for Frasier syndrome faces certain restraints as well. Limited awareness among healthcare professionals and the general public about this rare disorder can lead to underdiagnosis and delayed treatment. Moreover, the high cost of genetic testing and specialized treatments poses a challenge for patients and their families.
Despite these challenges, the market for Frasier syndrome presents several opportunities. The development of targeted therapies and personalized medicine approaches holds promise for improved outcomes in patients with Frasier syndrome. Furthermore, collaborations between research institutions, pharmaceutical companies, and advocacy groups can help drive research on better diagnostic tools and treatment modalities.
Key Features of the Study:
- This report provides in-depth analysis of the global Frasier syndrome market, including market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, with 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global Frasier syndrome market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Frasier syndrome market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Frasier syndrome market
Frasier Syndrome Market Segmentation:
- By Test Type
- Genetic Testing
- Ultrasound Testing
- Others
- By End User
- Hospitals
- Diagnostic Centers
- Research Institutes
- Others
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles
- Thermo Fisher Scientific
- Invitae Corporation
- GE Healthcare
- Koninklijke Philips N.V.
- Mindray Medical
- Siemens
- Canon Medical Systems Corporation
- FUJIFILM Sonosite Inc.
- ESAOTE SPA, SAMSUNGHEALTHCARE
- Empire Genomics Inc.
- BPL Medical Technologies
- Trivitron Healthcare
- Hitachi Healthcare
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Frasier Syndrome, By Test Type
- Market Frasier Syndrome, By End User
- Market Frasier Syndrome, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rising awareness about genetic disorders
- Limited awareness among healthcare professionals
- The development of targeted therapies and personalized medicine approaches
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Frasier Syndrome Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Frasier Syndrome Market, By Test Type, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Genetic Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Ultrasound Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
6. Frasier Syndrome Market, By End User, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Diagnostic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
7. Frasier Syndrome Market, By Region, 2020-2032, (US$ Mn)
- Introduction
- Market Share Analysis, By Country, 2023and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021-2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Test Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Invitae Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GE Healthcare
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Koninklijke Philips N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mindray Medical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Siemens
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Invitae Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Canon Medical Systems Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- FUJIFILM Sonosite Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- ESAOTE SPA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- SAMSUNGHEALTHCARE
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Empire Genomics Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- BPL Medical Technologies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Trivitron Healthcare
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hitachi Healthcare
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
9. Section
- Research Methodology
- About us
°ü·ÃÀÚ·á